title: Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
authors.affiliation: Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Shimizu
authors.affiliation: Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
authors.forename: Mai
authors.initials: M
authors.lastname: Hattori
authors.affiliation: Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Takeuchi
authors.affiliation: Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishikawa
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007642:Keratosis / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D035002:Lower Extremity; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D020156:Salicylic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D060726:Torso; D034941:Upper Extremity
chemical_list: D000970:Antineoplastic Agents; D007641:Keratolytic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D020156:Salicylic Acid